



AlloVir to Participate in the SVB Securities Global Biopharma Conference

February 1, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 1, 2023-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief Executive Officer Diana Brainard, M.D., will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 10:00 a.m. ET.

A live webcast and archived replay of the fireside chat will be available on the Investors & Press section of the AlloVir website at <https://ir.allovir.com>.

About AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.

AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on [Twitter](#) or [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230201005346/en/): <https://www.businesswire.com/news/home/20230201005346/en/>

Media and Investor:

Sonia Choi

AlloVir

schoi@allovir.com

Source: AlloVir, Inc.